Ricardo E. Carrión, PhD; Danielle McLaughlin, MA; Terry E. Goldberg, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1133-1142. doi:10.1001/jamapsychiatry.2013.1909
Carrión et al develop a predictive model of functional (social and role) outcome in a clinical high-risk sample for psychosis.
Alex Fornito, PhD; Ben J. Harrison, PhD; Emmeline Goodby, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1143-1151. doi:10.1001/jamapsychiatry.2013.1976
Fornito and colleagues used resting-state functional magnetic resonance imaging to characterize disease-related, risk-related, and symptom-related changes of corticostriatal functional circuitry in patients with first-episode psychosis and their unaffected, first-degree relatives.
Robin B. Jarrett, PhD; Abu Minhajuddin, PhD; Howard Gershenfeld, MD, PhD; et al.
free access
has audio
JAMA Psychiatry. 2013;70(11):1152-1160. doi:10.1001/jamapsychiatry.2013.1969
Jarrett and colleagues tested the efficacy of continuation phase cognitive therapy and fluoxetine for relapse prevention in a placebo-controlled randomized trial and compared the durability of prophylaxis after discontinuation of treatments.
-
Podcast:
Preventing Depressive Relapse and Recurrence in Higher-Risk Cognitive Therapy Responders: A Randomized Trial of Continuation Phase Cognitive Therapy, Fluoxetine, or Matched Pill Placebo
William R. Beardslee, MD; David A. Brent, MD; V. Robin Weersing, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1161-1170. doi:10.1001/jamapsychiatry.2013.295
Beardslee et al determine whether the positive effects of a group cognitive-behavioral prevention (CBP) program extended to longer-term (multiyear) follow-up.
Lewis L. Judd, MD; Pamela J. Schettler, PhD; William Coryell, MD; et al.
free access
JAMA Psychiatry. 2013;70(11):1171-1180. doi:10.1001/jamapsychiatry.2013.1957
In an observational, longitudinal study, Judd and coauthors determine the prevalence of overtly expressed irritability/anger and its effect on intake presentation and the long-term course of illness.
-
Editorial
When Depression Doesn’t Lead With Depression
Michael Craig Miller, MD
JAMA Psychiatry
Aaron S. Heller, MS; Tom Johnstone, PhD; Michael J. Peterson, MD, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1181-1189. doi:10.1001/jamapsychiatry.2013.2430
In a 6-month double-blind trial, Heller and coauthors examine changes in the neural circuits involved in emotion regulation resulting from 1 of 2 antidepressant treatments. See also the editorial by Miller.
-
Editorial
When Depression Doesn’t Lead With Depression
Michael Craig Miller, MD
JAMA Psychiatry
Helen Blair Simpson, MD, PhD; Edna B. Foa, PhD; Michael R. Liebowitz, MD; et al.
free access
has multimedia
JAMA Psychiatry. 2013;70(11):1190-1199. doi:10.1001/jamapsychiatry.2013.1932
Simpson et al compare the effects of 2 serotonin reuptake inhibitor augmentation strategies, risperidone or cognitive-behavioral therapy consisting of exposure and ritual prevention, vs pill placebo in adults with obsessive-compulsive disorder. See related editorial by Ressler.
-
Editorial
Augmenting Obsessive-Compulsive Disorder Treatment: From Brain to Mind
Kerry J. Ressler, MD, PhD; Barbara O. Rothbaum, PhD
JAMA Psychiatry
Robert H. Pietrzak, PhD, MPH; Jean-Dominique Gallezot, PhD; Yu-Shin Ding, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1199-1205. doi:10.1001/jamapsychiatry.2013.399
Pietrzak et al performed a cross-sectional positron emission tomography study under resting conditions among 3 study groups (healthy adults, adults exposed to trauma who did not develop posttraumatic stress disorder (PTSD), and adults exposed to trauma who developed PTSD). The [11C]methylreboxetine-binding potential of norepinephrine transporter availability was measured in the locus coeruleus, and PTSD symptom severity was assessed.
Ted Reichborn-Kjennerud, MD, PhD; Eivind Ystrom, PhD; Michael C. Neale, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1206-1214. doi:10.1001/jamapsychiatry.2013.1944
Reichborn-Kjennerud et al determine the structure of genetic and environmental risk factors for the symptoms of borderline personality disorder.
Scott S. Hall, PhD; Heidi Jiang, BS; Allan L. Reiss, MD; et al.
free access
JAMA Psychiatry. 2013;70(11):1215-1223. doi:10.1001/jamapsychiatry.2013.247
Hall et al identify large-scale resting-state networks in patients with fragile X syndrome that differ from those in control individuals matched on age, IQ, and severity of behavioral and cognitive symptoms.
Jonas F. Ludvigsson, MD, PhD; Abraham Reichenberg, PhD; Christina M. Hultman, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1224-1230. doi:10.1001/jamapsychiatry.2013.2048
Ludvigsson and coauthors examine the association between autism spectrum disorders and celiac disease.
Brian M. D’Onofrio, PhD; Quetzal A. Class, BS; Martin E. Rickert, PhD; et al.
free access
JAMA Psychiatry. 2013;70(11):1231-1240. doi:10.1001/jamapsychiatry.2013.2107
D’Onofrio et al estimate the extent to which the associations between early gestational age and offspring mortality and morbidity are the result of confounding factors in a population-based cohort study.
Meredith L. Wallace, PhD; Ellen Frank, PhD; Helena C. Kraemer, PhD
free access
JAMA Psychiatry. 2013;70(11):1241-1247. doi:10.1001/jamapsychiatry.2013.1960
Wallace et al demonstrate a novel exploratory approach to moderation analysis with a sample of 291 adults from a randomized clinical trial that compared an empirically supported psychotherapy and selective serotonin reuptake inhibitor pharmacotherapy as treatments for depression.